Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: A randomized study

Transplantation

Volumn 89, Issue 2, 2010, Pages 263-265

  Potena, Luciano ^a   Bianchi, Isidoro G ^a   Magnani, Gaia ^a   Masetti, Marco ^a   Coccolo, Fabio ^a   Fallani, Francesco ^a   Russo, Antonio ^a   Grigioni, Francesco ^a   Branzi, Angelo ^a   Ponticelli, Claudio ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRIACYLGLYCEROL;

BACTERIAL INFECTION; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LETTER; LUNG INFECTION; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; MYCOPHENOLIC ACID; SAFETY; SIROLIMUS;

EID: 76649119471     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c42b95     Document Type: Letter

References (23)

1. Zuckermann AO, Aliabadi AZ. Calcineurin-inhibitor minimization protocols in heart transplantation. Transpl Int 2009; 22: 78.
2. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
3. Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant 2006; 6: 671.
4. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantationof a nonrenal organ. N Engl J Med 2003; 349: 931.
5. Al-Aly Z, Sachdeva A, Philoctete Ashley JM, et al. Preliminary experience with mycopheno-late mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity. Nephrol-ogy (Carlton) 2006; 11: 151.
6. Manito N, Kaplinsky EJ, Roca J, et al. Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule. Clin Transplant 2005; 19: 304.
7. Sanchez V, Delgado JF, Morales JM, et al. Chronic cyclosporine-induced nephrotox-iciy in heart transplant patients: Long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2004; 36: 2823.
8. Baryalei M, Zenker D, Pieske B, et al. Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2003; 35: 1539.
9. Tedoriya T, Keogh AM, Kusano K, et al. Reversal of chronic cyclosporine nephrotoxic-ity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 2002; 21: 976.
10. Aleksic I, Baryalei M, Busch T, et al. Improvement of impaired renal function in heart transplant recipients treated with my-cophenolate mofetil and low-dose cyclo-sporine. Transplantation 2000; 69: 1586.
11. Angermann CE, Stork S, Costard-Jackle A, et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction inheart transplant recipients-The IMPROVED multi-centre study. Eur Heart J 2004; 25: 1626.
12. Ross H, Pflugfelder P, Haddad H, et al. Cy-closporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac al-lograft recipients. J Heart Lung Transplant 2008; 27: 197.
13. Schweiger M, Wasler A, Prenner G, et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transpl Immunol 2006; 16: 46.
14. Balfour IC, Srun SW, Wood EG, et al. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediat-ric heart transplantation patients. J Heart Lung Transplant 2006; 25: 518.
15. Trosch F, Rothenburger M, Schneider M, et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 2004; 52: 163.
16. Cockcroft D, Gault M. Prediction of creati-nine clearance from serum creatinine. Nephron 1975; 16: 31.
17. Scott NW, McPherson GC, Ramsay CR, et al. The method of minimization for allocation to clinical trials. A review. Control Clin Trials 2002; 23: 662.
18. Diekmann F, Budde K, Slowinski T, et al. Conversion tosirolimus for chronic allograft dysfunction: Long-term results confirm predictive valueofproteinuria.Transpl Int2008; 21: 152.
19. Stephany BR, Boumitri M, Budev M, et al. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease. J Heart Lung Transplant 2009; 28: 564.
20. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to siroli-mus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
21. Potena L, Fearon WF, Sydow K, et al. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: Modulation by sirolimus. Transplantation 2008; 85: 827.
22. Andrassy J, Graeb C, Rentsch M, et al. mTOR inhibition and its effect on cancer in transplantation. Transplantation 2005; 80(1 suppl): S171.
23. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48.